Literature DB >> 16673273

Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia.

Peter Johansson1.   

Abstract

The annual incidence of polycythemia vera (PV) and essential thrombocythemia (ET) is approximately 2 and 1.5 per 100,000 inhabitants, respectively, if based on large population surveys and adjusted to a standard population. Survival for ET patients does not differ from that of the general population. However, it appears that PV patients have a significantly higher mortality, at least for patients diagnosed before 1990.

Entities:  

Mesh：

Year:  2006        PMID： 16673273     DOI： 10.1055/s-2006-939430

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN： 0094-6176            Impact factor:   4.180


  20 in total

1.  Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: a population-based study.

Authors:  François Girodon; Gilles Bonicelli; Céline Schaeffer; Morgane Mounier; Serge Carillo; Ingrid Lafon; Paule Marie Carli; Inès Janoray; Emmanuelle Ferrant; Marc Maynadié
Journal:  Haematologica       Date:  2009-04-18       Impact factor: 9.941

2.  Essential thrombocythemia: Rare cause of chorea.

Authors:  Eswaradass Prasanna Venkatesan; Kalidoss Ramadoss; Ramasamy Balakrishnan; B Prakash
Journal:  Ann Indian Acad Neurol       Date:  2014-01       Impact factor: 1.383

Review 3.  Polycythemia as rare secondary direct manifestation of acromegaly: management and single-centre epidemiological data.

Authors:  Gabriele Zoppoli; Federico Bianchi; Andrea Bruzzone; Alessandro Calvia; Caterina Oneto; Caterina Passalia; Enrico Balleari; Davide Bedognetti; Elena Ponomareva; Elena Nazzari; Lara Castelletti; Lucio Castellan; Francesco Minuto; Riccardo Ghio; Diego Ferone
Journal:  Pituitary       Date:  2012-06       Impact factor: 4.107

Review 4.  Ruxolitinib for the treatment of patients with polycythemia vera.

Authors:  Jean-Jacques Kiladjian; Elliott F Winton; Moshe Talpaz; Srdan Verstovsek
Journal:  Expert Rev Hematol       Date:  2015-05-17       Impact factor: 2.929

Review 5.  [Skeletal manifestations of systemic hematologic disorders].

Authors:  J Luitjens; A Baur-Melnyk
Journal:  Radiologe       Date:  2021-11-24       Impact factor: 0.635

Review 6.  Essential thrombocythemia: past and present.

Authors:  Fabrizio Fabris; Maria Luigia Randi
Journal:  Intern Emerg Med       Date:  2009-07-28       Impact factor: 3.397

Review 7.  Jak-2 positive myeloproliferative neoplasms.

Authors:  Pablo J Muxí; Ana Carolina Oliver
Journal:  Curr Treat Options Oncol       Date:  2014-06

8.  The importance of cardiovascular risk factors for thrombosis prediction in patients with essential thrombocythemia.

Authors:  Danijela Lekovic; Mirjana Gotic; Natasa Milic; Predrag Miljic; Mirjana Mitrovic; Vladan Cokic; Ivo Elezovic
Journal:  Med Oncol       Date:  2014-09-16       Impact factor: 3.064

9.  Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study.

Authors:  Michael R Grunwald; John M Burke; David J Kuter; Aaron T Gerds; Brady Stein; Mark A Walshauser; Shreekant Parasuraman; Philomena Colucci; Dilan Paranagama; Michael R Savona; Ruben Mesa
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2019-06-13

10.  Philadelphia-negative chronic myeloproliferative neoplasms.

Authors:  Rosane Isabel Bittencourt; Jose Vassallo; Maria de Lourdes Lopes Ferrari Chauffaille; Sandra Guerra Xavier; Katia Borgia Pagnano; Ana Clara Kneese Nascimento; Carmino Antonio De Souza; Carlos Sergio Chiattone
Journal:  Rev Bras Hematol Hemoter       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.